Get the Stockscreener App
0.1083
2.87%
-0.0032
After Hours:
.11
0.0017
+1.57%
Lyra Therapeutics Inc stock is traded at $0.1083, with a volume of 1.38M.
It is down -2.87% in the last 24 hours and down -7.12% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$0.1115
Open:
$0.1127
24h Volume:
1.38M
Relative Volume:
1.08
Market Cap:
$6.92M
Revenue:
$1.47M
Net Income/Loss:
$-97.61M
P/E Ratio:
-0.0727
EPS:
-1.49
Net Cash Flow:
$-80.90M
1W Performance:
+3.14%
1M Performance:
-7.12%
6M Performance:
-58.17%
1Y Performance:
-97.66%
1-Day Range:
$0.1074
$0.115
1-Week Range:
$0.0955
$0.1246
52-Week Range:
$0.082
$4.71
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.1083 | 6.92M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com
Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com
Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com
Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com
Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com
QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com
Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com
Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com
Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel
An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com
Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News
Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World
Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia
Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com
TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com
Mateon Therapeutics (OTCMKTS:MATN) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com
Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com
A Closer Look at Lyra Therapeutics Inc (LYRA) Stock Gains - investchronicle.com
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
Lyra Therapeutics stock plunges to 52-week low of $0.16 - Investing.com India
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $4.50 - Defense World
Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Earns “Neutral” Rating from HC Wainwright - Defense World
Lyra Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Arbor Realty Trust Closes a $1.15 Billion Repurchase Facility to Unwind Two Outstanding Collateralized Loan Obligations - The Manila Times
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FDA Green Light: Lyra's Nasal Polyp Treatment Advances as 52-Week Data Shows Promise - StockTitan
Lyra Therapeutics reports Q4 EPS ($1.43), consensus (13c) - TipRanks
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Thursday - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
Chronic Rhinosinusitis Pipeline 2024: FDA Updates, Therapy - openPR.com
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):